Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Liabilities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Total Liabilities for 7 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 2.26% to $17.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.3 million, a 2.26% decrease, with the full-year FY2025 number at $17.3 million, down 2.26% from a year prior.
  • Total Liabilities was $17.3 million for Q4 2025 at Fulcrum Therapeutics, up from $16.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $34.5 million in Q2 2022 to a low of $14.2 million in Q1 2025.
  • A 5-year average of $23.0 million and a median of $23.4 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 33.02% in 2021, then grew 27.75% in 2022.
  • Fulcrum Therapeutics' Total Liabilities stood at $23.5 million in 2021, then grew by 18.25% to $27.7 million in 2022, then dropped by 18.89% to $22.5 million in 2023, then dropped by 21.41% to $17.7 million in 2024, then decreased by 2.26% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Total Liabilities are $17.3 million (Q4 2025), $16.5 million (Q3 2025), and $14.5 million (Q2 2025).